Amadea Britton
Impact in
- Infectious Diseases top 2%
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Health top 5%
- Vaccine Coverage and Hesitancy
Papers in
-
- SARS-CoV-2 and COVID-19 Research 23
- COVID-19 Clinical Research Studies 1
-
- Respiratory viral infections research 6
- Pneumonia and Respiratory Infections 2
- Co-authors
- Katherine E. Fleming-Dutra (12 shared papers)Zachary Smith (9 shared papers)Nong Shang (9 shared papers)Jennifer R. Verani (9 shared papers)Gordana Derado (9 shared papers)Emma K. Accorsi (9 shared papers)Stephanie J. Schrag (7 shared papers)H. Keipp Talbot (4 shared papers)
- Journals
- MMWR Morbidity and Mortality Weekly Report (12 papers)Open Forum Infectious Diseases (5 papers)JAMA (4 papers)Vaccine (4 papers)The Journal of Infectious Diseases (2 papers)
- Partner nations
- United StatesCanadaVietnam
In The Last Decade
Amadea Britton
36 papers receiving 2.1k citations
Amadea Britton's Hit Papers
Peers
Comparison fields: 5 of 77
- Infectious Diseases 1.2k
- Health 198
- Epidemiology 588
- Modeling and Simulation 86
- Toxicology 26
Countries citing papers authored by Amadea Britton
This map shows the geographic impact of Amadea Britton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amadea Britton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amadea Britton more than expected).
Fields of papers citing papers by Amadea Britton
This network shows the impact of papers produced by Amadea Britton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amadea Britton. The network helps show where Amadea Britton may publish in the future.
Co-authors
The 25 scholars most cited alongside Amadea Britton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 37 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants Hit paper breakdown → | 2022 | 512 |
| 2 | Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 Hit paper breakdown → | 2022 | 267 |
| 3 | Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023 Hit paper breakdown → | 2023 | 238 |
| 4 | 2022 | 122 | |
| 5 | 2022 | 112 | |
| 6 | Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024 Hit paper breakdown → | 2024 | 110 |
| 7 | 2021 | 109 | |
| 8 | Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2024 Hit paper breakdown → | 2024 | 108 |
| 9 | Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023 Hit paper breakdown → | 2023 | 101 |
| 10 | 2022 | 64 | |
| 11 | 2022 | 60 | |
| 12 | 2023 | 49 | |
| 13 | 2022 | 39 | |
| 14 | 2023 | 34 | |
| 15 | 2023 | 32 | |
| 16 | 2024 | 29 | |
| 17 | 2022 | 27 | |
| 18 | 2024 | 22 | |
| 19 | 2023 | 17 | |
| 20 | 2024 | 14 |
About Amadea Britton
Amadea Britton is a scholar working on Infectious Diseases, Epidemiology, Neurology, Toxicology and Microbiology, having authored 37 papers that have together received 2.2k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (23 papers), Respiratory viral infections research (6 papers), Long-Term Effects of COVID-19 (3 papers), Pneumonia and Respiratory Infections (2 papers), Streptococcal Infections and Treatments (1 paper), Bacterial Infections and Vaccines (1 paper), COVID-19 Clinical Research Studies (1 paper) and Per- and polyfluoroalkyl substances research (1 paper). The work is most often cited by research in Infectious Diseases (1.2k citations), Health (198 citations), Epidemiology (588 citations), Modeling and Simulation (86 citations) and Toxicology (26 citations). Amadea Britton has collaborated with scholars based in United States, Canada and Vietnam. Frequent co-authors include Katherine E. Fleming-Dutra, Zachary Smith, Nong Shang, Jennifer R. Verani, Gordana Derado, Emma K. Accorsi, Stephanie J. Schrag, H. Keipp Talbot, Sarah S. Long and Lauren E. Roper. Their work appears in journals such as MMWR Morbidity and Mortality Weekly Report, Open Forum Infectious Diseases, JAMA, Vaccine and The Journal of Infectious Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.